Both Teva and Sandoz have announced launches of generic naloxone nasal spray for the reversal of opioid overdose in the US, with Teva claiming first-to-market status. The Sandoz version is an authorized generic of Emergent BioSolution’s Narcan nasal spray. Teva’s version of Narcan was approved by the FDA in April 2019.
Opiant initially developed Narcan nasal spray, which was approved by the FDA in November 2015. Adapt Pharma, which acquired the US rights to Narcan in 2014, was later acquired by Emergent Biosolutions.
Sandoz Inc. President Keren Haruvi commented, “Now more than ever, it’s imperative that Americans have increased access to life-saving opioid overdose reversal medicines for themselves or a loved one. The launch of our authorized generic of Narcan Nasal Spray reinforces our commitment to delivering high-quality, affordable generic medicines and to do our part to help address the public health epidemic for people at risk for opioid overdose.”
Read the Teva press release.
Read the Sandoz press release.
